Hiroyuki Niihara

Hiroyuki Niihara

Auto-generated profile, based on publicly available information

Hiroyuki Niihara

Department of Dermatology, Shimane University Faculty of Medicine (H.N., E.M.), Matsue, Japan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
KFKoya Fukunaga
Koya Fukunaga
ETEri Tsukagoshi
Eri Tsukagoshi
MKMaiko Kurata
Maiko Kurata
YMYoshiko Mizukawa
Yoshiko Mizukawa
HNHiroyuki Niihara
Hiroyuki Niihara
YSYoshiro Saito
Yoshiro Saito

24 May 2024 in American Journal of Ophthalmology
Verified
Journal Article
Open access
MKMiho Kojima
Miho Kojima
HMHiroki Mieno
Hiroki Mieno
MUMayumi Ueta
Mayumi Ueta
MNMitsuko Nakata
Mitsuko Nakata
STSatoshi Teramukai
Satoshi Teramukai
CSChie Sotozono
Chie Sotozono
To investigate the incidence and prognostic factors of ocular sequelae in Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) cases arising between 2016 and 2018 in Japan, and compare the findings with those presented in the previous 2005-2007 survey. Retrospective, national trend survey. Dermatologic case report forms (CRFs) (d-CRFs) were sent to 257 institutions that treated at least 1 SJS/TEN case, and 508 CRFs were collected from 160 institutions. Ophthalmologic CRFs (o-CRFs) regarding patient demographic data, onset date, ocular findings (first appearance, day of worst severity, and final follow-up), topical treatment (betamethasone), outcome (survival or death), and ocular sequelae (visual disturbance, eye dryness) were sent to the ophthalmologists in those 160 institutions. The results of this survey were then compared with that of the previous 2005-2007 survey. A total of 240 cases (SJS/TEN: 132/108) were included. The incidence of ocular sequelae incidence was 14.0%, a significant decrease from the 39.2% in the previous survey (SJS/TEN: 87/48). In 197 (82.1%) of the cases, systemic treatment was initiated within 3 days after admission, an increase compared to the previous survey (ie, treatment initiated in 82 [60.7%] of 135 cases). Of the 85 cases with an Acute Ocular Severity Score of 2 and 3, 62 (72.9%) received corticosteroid pulse therapy and 73 (85.9%) received 0.1% betamethasone therapy; an increase compared to the 60.0% and 70.8%, respectively, in the previous survey. Ocular-sequelae-associated risk factors included Acute Ocular Severity Score (P < .001) and specific year in the survey (P < .001). The ophthalmologic prognosis of SJS/TEN has dramatically improved via early diagnosis, rapid assessment of acute ocular severity, and early treatment.